Aytu BioPharma (AYTU) Stock Price, News & Analysis

Company Overview

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States.

Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.

Key Stats

• Today's Range: $2.36 to $2.40
• 50-Day Range: $2.06 to $2.40
• 52-Week Range: $1.65 to $3.07
• Volume: 36,861 shs
• Average Volume: 51,237 shs
• Market Capitalization: $25.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.75
• Consensus Rating: Hold

Aytu BioPharma Stock Analysis - MarketRank™

Aytu BioPharma scored higher than 58% of companies evaluated by MarketBeat, and ranked 381st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Aytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Aytu BioPharma has a consensus price target of $10.75, representing about 348.9% upside from its current price of $2.40.

Amount of Analyst Coverage

Aytu BioPharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aytu BioPharma are expected to grow in the coming year, from ($0.73) to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aytu BioPharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aytu BioPharma is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aytu BioPharma has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.20% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 12.49, which indicates bearish sentiment.

Change versus previous month

Short interest in Aytu BioPharma has recently decreased by 5.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aytu BioPharma does not currently pay a dividend.

Dividend Growth

Aytu BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.00

News Sentiment

Aytu BioPharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aytu BioPharma this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.90% of the stock of Aytu BioPharma is held by insiders.

Percentage Held by Institutions

33.49% of the stock of Aytu BioPharma is held by institutions.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 8/19/2026
• Next Earnings (Estimated): 9/29/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AYTU
• CIK: 1385818
• Web: aytubio.com
• Phone: (720) 437-6580
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aytu BioPharma: $10.75
• High Price Target: $14.50
• Low Price Target: $7.00
• Potential Upside/Downside: +350.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.56 million
• Net Margins: -60.17%
• Pretax Margin: -59.49%
• Return on Equity: -69.93%
• Return on Assets: -13.25%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.12
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $66.38 million
• Price / Sales: 0.39
• Cash Flow: $0.38 per share
• Price / Cash Flow: 6.34
• Book Value: $2.11 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 10,730,000
• Free Float: 10,207,000
• Market Cap: $25.63 million
• Optionable: Not Optionable
• Beta: 0.25